Nicotinamide Mononucleotide (NMN)
NAD+ precursor; early human trials suggest metabolic & energy benefits, especially in older adults.
Evidence last reviewed: 04 Apr 2026
Nicotinamide Mononucleotide (NMN) is a promising NAD+ precursor that may enhance metabolic health and energy levels, particularly in older adults. However, its regulatory status and potential risks warrant caution.
May fuel pre-existing cancer cell growth in preclinical models (NAD+ supports cell proliferation) — human significance unclear
FDA has raised exclusion concerns for NMN as a dietary supplement — regulatory status is legally ambiguous in the US
Summarized study outcomes with population, design, grade, and effect data.
Current evidence shows NMN reliably raises NAD+ levels and may improve insulin sensitivity and muscle endurance in older adults. However, the long-term effects and safety in humans remain unclear, and more research is needed.
NAD+ levels / metabolic markersOlder adults; insulin-resistant individuals · RCTs (phase I/II)Moderate
Reliably raises blood NAD+; some improvements in insulin sensitivity & muscle endurance in older adults.
Stacks containing Nicotinamide Mononucleotide (NMN)
Public community stacks that include this ingredient.